Several other brokerages have also recently weighed in on NOVN. JPMorgan Chase & Co. set a CHF 84 price target on shares of Novartis and gave the company a neutral rating in a research report on Wednesday, January 10th. Morgan Stanley set a CHF 92 price target on shares of Novartis and gave the company a buy rating in a research report on Friday, December 1st. Bank of America set a CHF 87 target price on shares of Novartis and gave the stock a sell rating in a research report on Wednesday, December 6th. Sanford C. Bernstein set a CHF 97 target price on shares of Novartis and gave the stock a buy rating in a research report on Thursday, October 26th. Finally, Societe Generale set a CHF 95 target price on shares of Novartis and gave the stock a buy rating in a research report on Wednesday, October 25th. Three investment analysts have rated the stock with a sell rating, six have given a hold rating and seven have issued a buy rating to the company’s stock. The stock presently has a consensus rating of Hold and a consensus price target of CHF 87.38.
Novartis (NOVN) opened at CHF 82.90 on Monday. The stock has a market capitalization of $215,430.00 and a PE ratio of 30.70. Novartis has a 52 week low of CHF 69.50 and a 52 week high of CHF 85.40.
Novan, Inc, a clinical-stage drug development company, focuses on the development and commercialization of nitric oxide-based therapies in dermatology. Its lead product candidate is SB204, a cosmetically elegant topical gel that targets multiple mechanisms of action for the treatment of acne vulgaris.
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.